Astellas Pharma, Inc. has chosen Medidata Solutions Rave 5.5 as its standard global solution for all clinical studies in Phases I-III during the next five years. Astellas plans to implement clinical trials using Medidata Rave 5.5 across North America, Asia, Europe and other regions. According to the company, the selection was based on Medidata’s understanding of the requirements of the global clinical development process and its reliable and secure hosting and help desk services and s...